{"entity":{"id":"camonsertib","kind":"drug","name":"Camonsertib","aka":[],"tldr":"Camonsertib is an oral serine/threonine kinase inhibitor from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.","summary":"Camonsertib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Hoffmann-La Roche, in metastatic cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Camonsertib","url":"https://clinicaltrials.gov/search?intr=Camonsertib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04589845"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral serine/threonine kinase inhibitor","mechanism":"A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/camonsertib/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}],"trial":[{"id":"nct04589845","kind":"trial","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","route":"/trials/nct04589845/"}]}}